Actively Recruiting
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Led by Barbara Ann Karmanos Cancer Institute · Updated on 2025-07-08
N/A
Participants Needed
1
Research Sites
973 weeks
Total Duration
On this page
Sponsors
B
Barbara Ann Karmanos Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
CONDITIONS
Official Title
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed solid tumor or hematologic malignancy, or awaiting biopsy or surgery for cancer evaluation of a detected mass
- Able to lie still during the PET scan
- Body size suitable to enter the PET scanner gantry
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here